All posts by imreal

Top L.A. Facial Plastic Surgeon, Dr. Jacob Sedgh, is One of the First Exclusive Providers to Offer the New FDA-Approved Daxxify™, an Alternative to Botox Treatment


News Image

“Daxxify is one of the safest, newest and most effective treatments on the market for wrinkles and fine lines for many patients, and with fewer treatments necessary for results compared to Botox and other similar products,” says Dr. Jacob Sedgh.

Dr. Jacob Sedgh is pleased to announce that DAXXIFY™, the only long-lasting, peptide-powered wrinkle injection treatment, is now available at his practice. Well-respected Los Angeles plastic surgeon Dr. Sedgh is one of just a few select providers to currently offer this innovative treatment to patients. Daxxify is a new injectable wrinkle treatment that’s FDA-approved to improve the appearance of moderate to severe glabellar lines, frown lines or “elevens” between the eyebrows. It can be used off-label to treat other wrinkles, like forehead furrows, crow’s feet and bunny lines, as well as platysmal bands in the neck and dimpling of the chin. As with other toxins, it can also be injected into the masseter muscles to soften a square, bulky jaw while reducing the clenching and grinding associated with TMJ. Like Botox, Dysport, and Xeomin, Daxxify (a.k.a. Daxi) works by temporarily blocking the release of the neurotransmitter that causes muscle movement. This smooths the “dynamic wrinkles” and prevents new expression lines from forming. What’s unique about Daxxify is its longevity with clinical studies showing an improvement in frown lines for six to nine months (compared to the standard three to five-month result offered by previously approved neuromodulators, like Botox). Daxxify is safe and effective for most patients and is unique because it is the only formulation that uses a novel peptide as a stabilizer and does not contain human or animal byproducts. With 20 years of research behind it and the largest phase-3 clinical trial program done on frown line treatment, patients can feel confident that this treatment is safe on most skin types.

“Daxxify is one of the safest, newest and most effective treatments on the market for wrinkles and fine lines for many patients, and with fewer treatments necessary for results compared to Botox and other similar products,” says Dr. Jacob Sedgh.

More about Dr. Jacob Sedgh:

With the benefit of two decades of medical training and practical experience at top medical institutions in the United States, Dr. Jacob Sedgh combines mastery of medical knowledge and surgical skills with the attention and perfection of a sculptor, delivering highly-personalized patient care. Dr. Sedgh attended the University of California, San Diego School of Medicine, receiving honors and recognition signifying his achievements as a top-tier graduate and completed a surgical internship at the University of California, San Francisco. He concluded his residency in otolaryngology and head and neck surgery at the prestigious University of Pittsburgh Medical Center. Dr. Sedgh then completed a fellowship at Penn State Hershey Medical Center focusing on facial cosmetic and reconstructive surgery. Whether it is the finesse of rhinoplasty to achieve a refined nose or the extensive reconstructive work on cancer patients to optimally restore form and function, board-certified facial plastic surgeon Dr. Jacob Sedgh creates beautiful, natural results at his clinic located at 9201 Sunset Blvd, Suite 404 in West Hollywood, CA. For more information or to schedule a consultation, please call 310-504-7604 or visit http://www.sedghplasticsurgery.com.

Share article on social media or email:

10PM Curfew is Partnering with Cora to End Period Stigma


Social Publisher Network 10PM Curfew has joined forces with Cora, a renowned brand specializing in clean period and body care products, to challenge the long-standing stigma surrounding menstruation. Through this partnership, 10PM Curfew and Cora aim to bring an end to the societal taboos associated with periods that have persisted for decades.

Kicking off on National Menstruation Day (5/28), a social media campaign titled “Period Day” was hosted on 10PM Curfew‘s popular TikTok meme account, @girls. The campaign’s primary focus is to empower individuals who menstruate and break the barriers surrounding the topic.

Starting from the inaugural date on May 28th, and continuing on the 28th day of the following three months, @girls will exclusively share period-related content sponsored by Cora. By addressing the subject head-on, this collaboration aspires to bridge the information gap that stems from treating periods as a forbidden and undisclosed matter, and ultimately eradicate the stigma associated with menstruation across all age groups.

Keep an eye on @girls on the 28th of each month, from now until July, for exclusive content related to periods sponsored by the knowledgeable experts at Cora.

###

About 10PM Curfew: 10PM Curfew is the largest female lifestyle social publisher network, with a monthly reach of 2 billion views across Instagram, TikTok & Snapchat. Their network of mainstream owned and operated handles is continuously growing. Their global team of content strategists is always at the forefront of virality, cultivating and creating highly engaged content for unique communities throughout the network.

Share article on social media or email:

Flourish Research Expands with New Acquisitions in North Carolina and Alabama


“Both partnerships will augment our existing capabilities and allow us to expand into new markets as we continue our journey to become a leader in clinical site services with a focus on diverse and underserved patient populations.” – Reinhold Schulz, CEO

Flourish Research announces the acquisition of two companies, AMC Research in Charlotte, North Carolina, and Central Research Associates (CRA) in Birmingham, Alabama. AMC is a therapeutically focused Alzheimer’s Disease research site and CRA is a multi-therapeutic site. Both acquisitions complement Flourish’s strategy of acquiring and integrating best-in-class sites.

Reza Bolouri, MD, is a board-certified neurologist and founder of AMC. Dr. Bolouri has been key to AMC’s success with more than 20 years of clinical research experience in Alzheimer’s and related dementias. AMC provides Flourish with additional scale in its existing Alzheimer’s Center of Excellence and access to a new and densely patient-populated market in Charlotte, North Carolina.

“Through this partnership, we can add value to the Flourish platform by augmenting their already existing Alzheimer’s capabilities,” Dr. Bolouri said.

CRA, founded in 2016 by William Whitley, PharmD, conducts Phase II-IV clinical trials across various therapeutic areas. The site is located on the campus of St. Vincent’s Hospital in Birmingham, Alabama. CRA is a leading national enroller in vaccine studies. CRA will provide Flourish with additional scale in cardiometabolic, pediatrics, orthopedics, and women’s health capabilities.

“My team and I are thrilled to have the opportunity to partner with Flourish Research,” Dr. Whitley said. “We look forward to working with the team at Flourish and the growth that we can achieve together in the future.”

Reinhold Schulz, CEO of Flourish Research, said “We are confident that both AMC and CRA will be great additions to our growing organization. Both partnerships will augment our existing capabilities and allow us to expand into new markets as we continue our journey to become a leader in clinical site services with a focus on diverse and underserved patient populations.”

About Flourish

Flourish Research is a leading clinical trial organization, created to strategically acquire, integrate, and operate the best clinical trial sites in North America. Flourish started as some of the most recognized trial sites in the industry. The wholly owned, fully integrated company has locations in Alabama, Florida, Illinois, North Carolina, Pennsylvania, and Texas. Flourish sites conduct Phase I-IV studies across therapeutic areas where they have deep expertise in Cardiology/Metabolic Disease, CNS, and Vaccines.

Share article on social media or email:

Minuendo Seeks Support from Indiegogo Community For New Earplugs


Support the Minuendo LIVE earplugs Indiegogo campaign

Seeking Indiegogo backers for the Minuendo LIVE earplugs

We are very pleased to announce the launch of our Indiegogo campaign, and look forward to bringing our third Minuendo earplug to market, with support of the Indiegogo community.

Minuendo, a leading manufacturer of patented earplugs, announced the launch of an Indiegogo campaign. Minuendo requests financial support and resources from the Indiegogo community, so that it can start manufacturing and shipping its new earplug product, Minuendo LIVE 17dB. Campaign pricing for Minuendo LIVE earplugs is heavily discounted for early backers.

Hearing is critical to communication with family, friends, in work settings, and when out in public. Minuendo strives to increase the longevity of this communication, through education about hearing health, and by offering methods for protection. Its products aim to provide safe auditory experiences for consumers, including concertgoers and musicians.

Moderate sound levels in concert performance situations can be harmful over time. For those who have frequent exposure to loud sound levels, they may suffer from hearing damage and tinnitus. Some damage can occur near-instantaneously, such as when exposed to loudspeaker feedback during a concert. The development of some hearing loss conditions is cumulative over time. This includes Noise Induced Hearing Loss (NIHL). There are no current treatments that have shown to be effective in reversing the course of hearing loss.

By using a patented membrane system, Minuendo’s approach to hearing protection is considered by many to be more advanced than many other products in the hearing protection market. Building on the success of its Adjustable earplugs,the company has created Minuendo LIVE to provide consumers with the perfect balance between sound reduction and quality – all at a lower price point than the adjustable model. Supporting this campaign will allow Minuendo to bring a much-needed new product to consumers that need a well-rounded hearing protection solution.

“We are very pleased to announce the launch of our Indiegogo campaign, and look forward to bringing our third Minuendo earplug to market, with support of the Indiegogo community,” said Chief Product Officer and Co-founder, Tom Trones, Minuendo. “This campaign will help us bring our LIVE earplugs to consumers who want to protect themselves without compromising on the experience.”

Key Features:


  • Natural flat frequency response
  • 17dB attenuation
  • Superior sound quality
  • Designed for comfort
  • Based on patented membrane design
  • No electronics or batteries
  • Selection of 11 ear tips
  • Premium accessories
  • Designed and manufactured in Norway

Although Minuendo earplugs are primarily designed for concertgoers and musicians, early results have shown they are beneficial in other use cases. This includes riding motorbikes, bartending, working with children, and hyperacusis treatment.

For more information, please visit Indiegogo https://www.indiegogo.com/projects/minuendo-live-earplugs-goodbye-to-muffled-sound/coming_soon

About Minuendo

At Minuendo we are passionate about sound and the sense of hearing. We are equally concerned about the state of hearing for consumers as well as professionals, ranging from musicians to workers in the construction industry.

Minuendo was founded in 2018 by a team with extensive experience from acoustics, hearing protection and product development. Our mission is to deliver category defining hearing protection products and solutions that provides real protection for the sense of hearing.

Minuendo was awarded the prestigious Red Dot Design Award for a Healthcare Brand in 2020, as well as the International Sound Awards in four categories.

Share article on social media or email:

Los Angeles and San Diego TMJ Treatment Specialist, Dr. Bob Perkins, Recognized as a 2023 Top Patient Rated Dentist by Find Local Doctors


News Image

“It is always an honor to receive this award. Helping my patients attain relief from the discomfort of TMJ and/or sleep apnea is so rewarding” says Dr. Bob Perkins.

With over 30 years of experience treating TMJ disorders, as well as cosmetic and restorative dentistry to correct the bite and realign the jaw, Dr. Bob Perkins has been a trusted dentist for countless patients. He has been selected for this distinguished award from Find Local Doctors as a result of his exceptional patient reviews and five-star ratings across multiple online sources. Find Local Doctors is an online directory that helps consumers quickly locate qualified and reputable physicians and dentists in their area. Dr. Bob Perkins is widely known as a true pioneer and expert in his field, and one of the best neuromuscular dentists in the country. He utilizes cutting-edge equipment and the finest materials, techniques and advanced technology to treat temporomandibular disorder (TMJ), sleep apnea and other issues. Dr. Perkins has significant training and experience to help determine the root cause of the problem. He offers effective treatment options, providing relief with unique and efficient repositioning therapies to heal pain in the jaw, neck and teeth relating to TMJ, with the goal of correcting the bite and realigning the jaw to support excellent oral health. Additionally, Dr. Perkins’ continuing education in orthodontics, cosmetic dentistry and facial aesthetics have furthered his commitment to helping his patients obtain proportional facial structures, non-constricted pathways and life without TMJ pain. Creating and supporting healthy and beautiful smiles is what he is most passionate about, and it shows with his large number of satisfied patients.

“It is always an honor to receive this award. Helping my patients attain relief from the discomfort of TMJ and/or sleep apnea is so rewarding” says Dr. Bob Perkins.

More About Dr. Bob Perkins:

A recognized leader, author and specialist in the field of TMJ, Dr. Bob Perkins began his undergraduate educational training at the University of Southern California. He then attended the Las Vegas Institute for Advanced Dental Studies, where he furthered his knowledge in cosmetic dentistry, orthodontics and TMJ disorders. Dr. Perkins is an expert in the field of TMD/TMJ and uses state-of-the-art equipment, techniques and up-to-date science to treat temporomandibular disorder. His treatments offer immediate relief from any stress or pain patients experience with the goal of correcting the bite and realigning the jaw in support of excellent oral health. Southern California TMJ and Sleep Clinic has three clinic locations in California. The offices are located in Malibu – (24955 Pacific Coast Highway, Ste. C100), Studio City – (12412 Ventura Blvd., Suite 1 ) and San Diego – (450 A Street #410.) For more information or to schedule a consultation, please visit http://www.socaltmjandsleepcenter.com or call 323-924-3790.

Share article on social media or email:

Top Marietta, Georgia Family Dental Practice Changes Practice Name to Autumn Dental


News Image

“I am thrilled for the opportunity to foster long-lasting relationships with my patients and help them achieve their dental health goals at Autumn Dental,” says Dr. Nicole Barnett.

Autumn Dental provides those in the Marietta and greater Atlanta area with exceptional, personalized dentistry for the entire family. Dr. Nicole Barnett and her team deliver a warm and friendly dental experience and strive to exceed each patient’s expectations. Dr. Barnett has been treating patients at the office for the past two and a half years and is excited to continue to offer the same premier level of comprehensive dental care under the new practice name. Autumn Dental has a wide menu of services for patients, including general dentistry, cosmetic dentistry, and restorative dentistry and is equipped for those with special needs and dental anxiety. Dr. Barnett utilizes state-of-the-art dental technology and cutting-edge procedures in order to help her clients maintain healthy, attractive smiles. When it comes to dentistry, Autumn Dental’s ultimate goal is to make sure clients feel as comfortable as possible and make receiving the oral health care they need convenient.

“I am thrilled for the opportunity to foster long-lasting relationships with my patients and help them achieve their dental health goals at Autumn Dental,” says Dr. Nicole Barnett.

More about Dr. Nicole Barnett:

Dr. Nicole Barnett attended Auburn University, graduating summa cum laude with a degree in Biomedical Sciences. While there, she was a member of the Auburn University Gymnastics Team and was named SEC Scholar-Athlete of the Year and NCAA Academic All-American. Dr. Barnett attended dental school at the Medical College of Georgia in Augusta and was the recipient of the Hinman Dental Society Scholarship and Judson C. Hickey Memorial Scholarship. From there, she went on to complete additional training in a General Practice Residency at the University of Tennessee Medical Center in Knoxville. During her residency, she did rotations in oral and maxillofacial surgery, forensic dentistry, family medicine, anesthesiology and emergency medicine. While there, Dr. Barnett also gained valuable experience treating patients with dental phobias and special needs, handling dental emergencies in the ER, managing complex dental treatments, and treating patients in the OR under general anesthesia. After completing her residency, she moved to Atlanta and has been practicing as a general dentist for over a decade. For additional information about the dental services at Autumn Dental or to schedule an appointment please call (770) 980-6336 and visit http://www.AutumnDental.com.

Share article on social media or email:

Advantage Gold Founder Adam Baratta Steps Down, Managing Partner Expresses Gratitude and Excitement for New Pursuits


Advantage Gold Founder Adam Baratta

“Without Adam Advantage Gold simply would not exist. It is because of his vision, passion, and leadership, that we have become the gold standard in the industry,” said CEO Kirill Zagalsky.

Adam Baratta, the co-founder of Advantage Gold and Brentwood Research, has announced that he will be stepping down from his role of Managing Partner of each entity to pursue new opportunities. Baratta expressed his gratitude to his entire team for their support and hard work, which has been the main driver of the company’s success over the last nine years.

Baratta built Advantage Gold into the leading precious metals dealer in the United States with his unwavering commitment to education and superior customer service. “Advantage Gold was founded on the fundamental belief that there was a better way to operate in the precious metals industry,” Baratta said. “Looking back on the past nine years, I am filled with immense pride at the progress we have made. The AG family has remained resolute in our commitment to delivering exceptional value, which has propelled us to the forefront of the industry and earned us the ranking as the highest-rated firm in the country. As I depart, I am confident that the company will continue to build on its momentum and achieve even greater success.”

Under his leadership, Baratta transformed the start-up publishing firm Brentwood Research into one of the fastest-growing financial publishers in the country, producing two #1 national bestselling books, Gold Is A Better Way and The Great Devaluation. He has a passion for this storytelling that he intends to expand upon in the next stage of his career.

“As a writer and content producer, I hold the view that we must be free to explore diverse ideas that go beyond the confines of a single subject,” said Adam Baratta. “I am excited about expanding my writing scope beyond finance to provide valuable storytelling that can help us navigate through the complexities of the present era.”

CEO Kirill Zagalsky expressed his appreciation for Adam’s contributions to the company and wished him well in his new pursuits. “Without Adam Advantage Gold simply would not exist. It is because of his vision, passion, and leadership, that we have become the gold standard in the industry. Adam will forever be a loved and admired member of the Advantage Gold family. We wish him all the best in his future endeavors,” said Zagalsky.

Advantage Gold will continue to focus on its mission of providing “the best process, the best service, and the best value” in the precious metals industry.

Share article on social media or email:

Clinical Lab Services Market at $168 Billion, finds New Kalorama Information Report


“COVID-19 testing demand increased the market by more than $31 billion over the year.”

The global market for clinical laboratory services grew to an estimated $168.3 billion during 2022. This is according to Kalorama Information’s recent report, Clinical Laboratory Services Market, 8th Edition. COVID-19 testing demand increased the market by more than $31 billion over the year.

Clinical laboratories offer a wide range of tests, including routine blood work, microbiology cultures, genetic testing, and specialized assays. The market encompasses both independent laboratories and those affiliated with hospitals, clinics, and research institutions.

Besides the remarkable and continued growth in 2022 due to COVID-19 demand, there are a number of drivers affecting steady growth for this market. Among these are an aging population, a growing incidence of chronic diseases and management, increasing emphasis on diagnosis and disease monitoring, and growth in advanced laboratory testing technologies and practices.

Specifically, key factors driving the growth of the clinical laboratory services market include:


  • Increasing prevalence of chronic diseases: The rising incidence of chronic conditions, such as cardiovascular diseases, cancer, and diabetes, necessitates frequent laboratory testing for diagnosis, disease monitoring, and treatment adjustment.
  • Technological advancements: Advances in laboratory technology and automation have improved testing accuracy, efficiency, and turnaround time. This enables laboratories to handle larger volumes of tests, leading to increased demand.
  • Aging population: The global aging population contributes to the growth of laboratory testing as elderly individuals often require more frequent medical evaluations and disease monitoring.
  • Emphasis on personalized medicine: The shift towards personalized healthcare approaches, driven by advancements in genomics and molecular diagnostics, has increased the demand for specialized laboratory tests tailored to individual patients.
  • Infectious disease outbreaks: Outbreaks of infectious diseases, such as the COVID-19 pandemic, significantly increase the demand for diagnostic testing services. These events highlight the importance of robust laboratory infrastructure and rapid testing capabilities.
  • Increasing healthcare expenditure: Governments and private sectors worldwide are investing more in healthcare infrastructure, including clinical laboratory facilities, to meet the growing demand for diagnostic services.

There are also a number of inhibitors to growth such as the growing emphasis to reduce health costs and uncertain economic conditions. Specifically, challenges to market growth include:

  • Automation plays a significant role in clinical laboratory services, helping to improve efficiency, accuracy, and turnaround time. Technological advancements, such as robotics, artificial intelligence (AI), machine learning, and digital pathology, are increasingly integrated into laboratory processes, aiding in the interpretation of test results and improving overall laboratory operations.
  • Clinical laboratory services are subject to regulatory oversight and quality standards to ensure accurate and reliable test results. In the United States, the Centers for Medicare and Medicaid Services (CMS) regulates laboratory services through the Clinical Laboratory Improvement Amendments (CLIA) program. International standards, such as ISO 15189, also provide guidelines for laboratory quality management systems.
  • The clinical laboratory services market has witnessed significant consolidation in recent years, with larger companies acquiring smaller laboratories to expand their service offerings and geographic reach. This consolidation trend is driven by economies of scale, access to specialized expertise, and the need to navigate the changing healthcare landscape.

The clinical laboratory services market is expected to continue growing as the demand for accurate and timely diagnostic testing remains essential for effective healthcare delivery.

For more information or to purchase the market research report “Clinical Laboratory Services Market, 8th Edition”, visit: https://kaloramainformation.com/product/clinical-laboratory-services-market-8th-edition/.

ABOUT KALORAMA INFORMATION

Kalorama Information, part of Science and Medicine Group, is the leading publisher of market research in healthcare areas, including in vitro diagnostics (IVD), biotechnology, medical devices, and pharmaceuticals. Science and Medicine Group supports companies seeking to commercialize the rapidly changing marketplace at the intersection of science, medicine, and technology. Comprised of industry-leading brands, Science and Medicine Group serves analytical instrument, life science, imaging, and clinical diagnostic companies by helping them create strategies and products to win markets and provide platforms to digitally engage their markets through a variety of innovative solutions. Kalorama Information produces 30 reports a year. The firm offers a Knowledge Center, which provides access to all published reports.

Share article on social media or email:

Greenlight Guru Modernizes Validation Approach to Streamline Software Implementation and Adoption for Medical Device Companies


https://www.greenlight.guru/

We’re excited to be modernizing our validation approach at Greenlight Guru because it will allow us to release software faster and improve the pace of innovation without jeopardizing compliance for our customers.

Greenlight Guru, the leading provider of cloud-based software for MedTech companies, today announced that it is adopting an automated, risk-based approach to software validation and strategically updating its Software Validation Package for customers. The modernized approach is in line with FDA guidance on Computer Software Assurance (CSA) and requirements of ISO 13485:2016 to ease the burden of validating new software for MedTech companies.

In the 2023 MedTech Industry Benchmark Report, one of the top challenges cited for managing quality was the cost and effort of validating new software tools and processes. This is mainly due to the more cumbersome approach to software validation—known as computer system validation (CSV)—that has traditionally been used in MedTech to meet regulatory requirements.

In 2022, FDA released a draft guidance, Computer Software Assurance for Production and Quality System Software, as part of a greater, industry-wide shift toward a more balanced approach to software validation for MedTech companies. This new approach will make it easier for MedTech companies to adopt new technology and explore the full potential of software tools for their businesses.

“The shift from CSV to CSA is a move toward a more balanced, risk-based approach to software validation,” says Brian Gaffney, CTO of Greenlight Guru. “We’re excited to be modernizing our validation approach at Greenlight Guru because it will allow us to release software faster and improve the pace of innovation without jeopardizing compliance for our customers. It also streamlines the implementation of our QMS solution for customers, which is a win for everyone.”

In light of the shift to CSA, Greenlight Guru’s Validation Package has been strategically updated to align with the best practices and requirements in the FDA’s guidance on Computer Software Assurance and ISO/TR 80002-2:2017, Validation of software for medical device quality systems. The Validation Package will enable teams to efficiently and effectively implement and adopt the latest software enhancements and functionality while assuring compliance with evolving validation requirements.

“Modernizing our validation processes helps ensure we’re doing everything possible to help our customers easily implement Greenlight Guru and get their life-changing medical devices to the patients who need them most,” says David DeRam, CEO of Greenlight Guru. “Ultimately, this shift is about helping MedTech companies keep up with evolving industry requirements and focus their resources where they matter most.”

When asked about the benefits of the updated Software Validation Package, Greenlight Guru customer Mary Head, ISO 13485:2016 Lead Auditor and Document Control Team Lead at DNAe, shared the following:

“The vast majority of software platforms are not built for medical device companies and therefore require painstakingly hard and time-consuming validation processes. With Greenlight Guru, we do not have to do any of that. We are excited about this shift in the industry and it is such a value-add to partner with innovative companies like Greenlight Guru who are at the forefront of this evolution and making software validation even easier for medical device companies.”

This announcement of an updated software validation approach comes on the heels of Greenlight Guru’s recent launch of Risk Solutions, a first-of-its-kind complete risk management solution that leverages AI-generated insights with intuitive workflows aligned with ISO 14971:2019.

To learn more about Greenlight Guru’s approach to software validation, visit https://www.greenlight.guru/medical-device-software-validation.

About Greenlight Guru

Greenlight Guru provides the leading cloud-based solutions for MedTech companies to bring life-changing products to people faster, and with less risk. Greenlight Guru provides purpose-built quality management, product development, and clinical data management solutions that together help teams accelerate timelines, streamline compliance, and deliver high-quality products. With Greenlight Guru, companies across the globe are improving efficiency, speed, and quality in every aspect of their organization to get products to market faster and keep them on the market longer. For more information, visit http://www.greenlight.guru.

Media Contact

PR at Greenlight Guru

pr@greenlight.guru

Share article on social media or email:

New Hampshire’s $2.8B Life Science Industry Shows High Job Growth


News Image

“With a mission to bolster the economic vitality of our state, the BEA is constantly seeking opportunities to provide increased support to our valued partners and key industry sectors,” says Taylor Caswell, commissioner at BEA.

The New Hampshire Department of Business and Economic Affairs (BEA) today announced the findings of a statewide life sciences industry assessment, which found that the state’s life science workforce added 1,484 jobs, representing a 15.1% growth rate within the industry and 3.8% of the state’s total job growth between 2012 and 2021. To further ensure growth and support the $2.8 billion sector, the BEA conducted a comprehensive assessment of New Hampshire’s life science sector. One of the findings was that the state would benefit from a life science association to nurture, protect and grow the industry, while providing networking, talent attraction and mentorship opportunities for life science companies, entrepreneurs and students.

The Camoin Associates study found that the life sciences industry saw $4.3 billion in sales in 2021 and represents 11,290 jobs, with average salaries of $130,848 per year. The industry’s top group is medical device manufacturing, with 31% of all life science jobs, followed by research and development services (26%), medical equipment and supplies manufacturing (23%), pharmaceutical and medicine manufacturing (16%) and medical and diagnostic laboratories (4%).

“With a mission to bolster the economic vitality of our state, the BEA is constantly seeking opportunities to provide increased support to our valued partners and key industry sectors,” says Taylor Caswell, commissioner at BEA. “This new strategy will help make our life sciences sector even more robust – allowing for workforce growth, strengthened partnerships and igniting fresh innovations within this thriving industry.”

The report reinforces the need for a New Hampshire-based life sciences industry association to drive peer-level sector support, recruitment and advocacy. Thanks to leading industry partners, this concept has been in development for the past several years and has now officially launched as New Hampshire Life Sciences (NHLS).

The report will also serve as the basis for a new series of strategies to support the industry’s growth. They include continued outreach regarding relevant market data, forging cross-industry workforce partnerships, establishing acceleration and incubator programs to address workforce gaps, and expanding marketing communications to amplify the industry.

“Right here in New Hampshire, an entirely new industry in biomanufacturing is being created, innovative treatments for the world’s deadliest cancers are transforming patient care, and vaccines that are preventing disease around the globe are being developed,” said Andrea Hechavarria, the new president and CEO of the state’s first-ever Life Science Association (NHLS). “NHLS has been formed to support these breakthroughs, the companies and employees that have created them and ultimately the patients that receive them.”

One of the state’s leading life sciences organizations is the Advanced Regenerative Manufacturing Institute (ARMI), a nonprofit focused on the development of large-scale manufacturing of engineered tissues and tissue-related technology. Manchester-based ARMI was awarded a five-year, $51 million grant to boost its efforts. It has since been granted $44 million in Build Back Better funding.

Other notable Granite State life science expansions include Novocure, a global oncology and medical device company that recently announced a $9.5 million expansion in the heart of downtown Portsmouth in 2021. The company ranked second for total industry research and development spending in 2022. This year, Detact Diagnostics, a Netherlands-based life sciences company that produces bacterial- and viral-detection solutions, established its U.S. headquarters and laboratories in Keene. Lonza Biologics (global vaccine manufacturer with operations in Portsmouth) and PCI Pharma Services (a pharmaceutical outsourcing company with operations in Bedford) are both currently in the process of significant expansions of their manufacturing campuses.

“New Hampshire’s vibrant life sciences industry and well-documented innovation climate have always gone hand-in-hand with our company’s patient-forward culture of growth,” said Bill Doyle, executive chairman of Novocure. “We look forward to finishing the construction of our new flagship facility in Portsmouth that will provide space for Novocure’s growing employee base and world-class training and development center. We are proud to play a role in shepherding the continued growth of the Granite State’s robust life sciences community.”

New Hampshire fosters a business-friendly environment where life science companies can benefit from a top-tier workforce, access to an R1 research institution at the University of New Hampshire, and close proximity to the global life science hub in Boston.

To read the full life science industry summary and strategy, please visit https://www.nheconomy.com/about-us/bea-reports.

About the New Hampshire Department of Business and Economic Affairs (BEA)

The Department of Business and Economic Affairs is dedicated to enhancing the economic vitality of the State of New Hampshire while promoting it as a destination for domestic and international visitors. For more information, visit http://www.nheconomy.com or http://www.choosenh.com.

Share article on social media or email: